Pharmacological treatment options for panic disorder in children and adolescents.

Abstract:

:Although panic disorder usually emerges in early to middle adulthood, adults with panic disorder often retrospectively report that their panic symptoms began in childhood or early adolescence. The majority of these juvenile cases are being misdiagnosed, and/or do not come to clinical attention. Awareness of early-onset panic disorder, as well as a more precise definition of early signs and possible clinical subtypes, can favour timely diagnosis and treatment, reduce clinical impairment and improve the prognosis of these patients. In the context of a multimodal approach, pharmacological treatment can be helpful. This review focuses on the empirical evidence of pharmacotherapy in early-onset panic disorder, including selective serotonin re-uptake inhibitors, benzodiazepines and tricyclics. The data supporting efficacy are still limited, and no controlled studies are available. Practical guidelines for the management of these patients are provided, including treatment of the most frequent psychiatric comorbidities.

authors

Masi G,Pari C,Millepiedi S

doi

10.1517/14656566.7.5.545

keywords:

subject

Has Abstract

pub_date

2006-04-01 00:00:00

pages

545-54

issue

5

eissn

1465-6566

issn

1744-7666

journal_volume

7

pub_type

杂志文章,评审
  • Treatment options for lysosomal storage disorders: developing insights.

    abstract:INTRODUCTION:Lysosomal storage disorders (LSDs) are clinically heterogeneous disorders that result primarily from lysosomal accumulation of macromolecules in various tissues. LSDs are always progressive, and often lead to severe symptoms and premature death. The identification of the underlying genetic and enzymatic de...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.729039

    authors: van Gelder CM,Vollebregt AA,Plug I,van der Ploeg AT,Reuser AJ

    更新日期:2012-11-01 00:00:00

  • Radiocontrast-induced nephropathy and percutaneous coronary intervention: a review of preventive measures.

    abstract::Injectable and absorbable contrast media for the use in radiology, all of which contains iodine as an essential component, has been, and continues to be, one of the main sources of agents which cause hospital-acquired renal failure. Although numerous methods have been explored to prevent renal contrast damage, radioco...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.5.639

    authors: Mintz EP,Gruberg L

    更新日期:2003-05-01 00:00:00

  • 72nd Meeting of the American Heart Association. November 1999, Atlanta, Georgia, USA.

    abstract::The American Heart Association annual meeting must be one of the largest scientific gatherings, attracting over 30,000 delegates. The meeting at the end of last year was held in Atlanta, USA, the 2000 meeting will be in New Orleans, USA. The following highlights represent my own interests. ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type:

    doi:10.1517/14656566.1.3.581

    authors: Lunnon MW

    更新日期:2000-03-01 00:00:00

  • Treatment of bacterial vaginosis: what we have and what we miss.

    abstract:INTRODUCTION:The disturbing, foul-smelling discharge of bacterial vaginosis (BV) is a nuisance to women. Treatment possibilities for BV are limited and only achieve complete cure in 65 to 85% of cases. In most women, the condition relapses within weeks to months after treatment. AREAS COVERED:In search of new therapeu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.881800

    authors: Donders GG,Zodzika J,Rezeberga D

    更新日期:2014-04-01 00:00:00

  • Vinflunine for the treatment of breast cancer.

    abstract:INTRODUCTION:Breast cancer is the most frequently diagnosed cancer and the highest cause of cancer mortality in females worldwide. The development of drugs improving overall survival in late-stage metastatic breast cancer remains a challenge. Vinflunine is the most recently developed drug in the vinca alkaloid class. I...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1217991

    authors: Gourmelon C,Bourien H,Augereau P,Patsouris A,Frenel JS,Campone M

    更新日期:2016-09-01 00:00:00

  • Pharmacotherapy in inherited and acquired ventricular arrhythmia in structurally normal adult hearts.

    abstract::Introduction: Ventricular arrhythmias are often seen in association with structural heart disease. However, approximately a tenth of affected patients have apparently normal hearts, where such arrhythmias typically occur in young patients, are sometimes inherited and can occasionally lead to sudden cardiac death (SCD)...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1669561

    authors: Ortmans S,Daval C,Aguilar M,Compagno P,Cadrin-Tourigny J,Dyrda K,Rivard L,Tadros R

    更新日期:2019-12-01 00:00:00

  • Pharmacologic treatment of male breast cancer.

    abstract::Male breast cancer is an uncommon condition. It often occurs in settings in which there is an imbalance between androgens and oestrogens. Genetics plays an important role, as many cases are associated with mutations in BRCA2 or other genes. Male breast cancer occurs at an older age than female breast cancer and is fre...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903200634

    authors: Hayes TG

    更新日期:2009-10-01 00:00:00

  • Posaconazole: a new broad-spectrum antifungal agent.

    abstract::The rising incidence of invasive fungal infections and the emergence of broader fungal resistance have led to the need for novel antifungal agents. Posaconazole is a new member of the triazole class of antifungals. It is available as an oral suspension and has a favorable toxicity profile, has demonstrated clinical ef...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.8.1167

    authors: Kwon DS,Mylonakis E

    更新日期:2007-06-01 00:00:00

  • Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer.

    abstract::Lapatinib is a dual (ErbB-1 and ErB-2) receptor tyrosine kinase inhibitor (TKI) that was recently approved by the FDA for the treatment of advanced breast cancer. It shows synergy with trastuzumab, and has demonstrated clinical activity in trastuzumab-resistant tumour. This paper reviews the drug development of lapati...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.13.2189

    authors: Mukherjee A,Dhadda AS,Shehata M,Chan S

    更新日期:2007-09-01 00:00:00

  • Topical alprostadil cream for the treatment of erectile dysfunction.

    abstract::Erectile dysfunction (ED) has serious negative consequences on both sexual experience and emotional well being and affects a broad range of age groups. The prevalence of ED is associated with increasing age and has been reported to be as high as 70%. Although the disorder is common and underdiagnosed, its treatment ca...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.3.623

    authors: Becher E

    更新日期:2004-03-01 00:00:00

  • The pharmacological management of cardiovascular disease in people living with HIV (PLWH).

    abstract::ABSTARCT Introduction: Cardiovascular disease (CVD) continues to be an essential cause of morbidity and mortality among people living with human immunodeficiency virus infection (PLWH). Since the bulk of cardiovascular risk (CVR) factors are shared between PLWH and the general population, prevention and treatment stra...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1856075

    authors: Corbacho N,Mur I,Molas ME,Vidal F,Domingo P

    更新日期:2021-01-04 00:00:00

  • Sibutramine: current status as an anti-obesity drug and its future perspectives.

    abstract:BACKGROUND:Obesity has become a global epidemic with recent estimates of > 400 million obese adults. Despite this, there are few safe and effective pharmacological interventions for obesity. Sibutramine is a weight loss agent, for use as an adjuvant to a comprehensive program of calorie restriction, exercise and behavi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.12.2161

    authors: Sharma B,Henderson DC

    更新日期:2008-08-01 00:00:00

  • Advances in pharmacotherapy of vestibular and ocular motor disorders.

    abstract:INTRODUCTION:Vertigo and dizziness are common chief complaints of vestibular and ocular motor disorders (lifetime prevalence 30%). Treatment relies on physical, pharmacological, psychological and rarely surgical approaches. Eight groups of drugs are currently used in vestibular and ocular motor disorders, namely anti-v...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1610386

    authors: Zwergal A,Strupp M,Brandt T

    更新日期:2019-07-01 00:00:00

  • From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch study.

    abstract:PURPOSE:To assess ocular surface status and tolerability after switching glaucoma patients from dorzolamide/timolol to brinzolamide/timolol fixed combination (FC). METHODS:Six-month, multicenter, open-label, prospective study that switched 72 patients from dorzolamide/timolol to brinzolamide/timolol FC. Intraocular pr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1517/14656566.2011.589384

    authors: Rossi GC,Pasinetti GM,Sandolo F,Bordin M,Bianchi PE

    更新日期:2011-11-01 00:00:00

  • The trade-off dilemma in pharmacotherapy of COVID-19: systematic review, meta-analysis, and implications.

    abstract:INTRODUCTION:The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people worldwide and has contributed to over 650,000 deaths. This review synthesizes the literature on COVID-19 pharmacotherapy to inform practice and policymaking. A...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,meta分析

    doi:10.1080/14656566.2020.1792884

    authors: Khan S,Gionfriddo MR,Cortes-Penfield N,Thunga G,Rashid M

    更新日期:2020-10-01 00:00:00

  • Pharmacotherapy of Paget's disease of bone.

    abstract:INTRODUCTION:Paget's disease of the bone is a common condition in some populations, affecting almost 10% of older adults in western Europe. Though frequently asymptomatic, it can sometimes result in severe disabilities. Timely intervention is now able to arrest disease progression in the majority of patients. AREAS CO...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.662486

    authors: Reid IR

    更新日期:2012-04-01 00:00:00

  • Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?

    abstract:INTRODUCTION:Historically, there were few effective and durable treatments for metastatic melanoma. Recently, mutation based targeted therapies have revolutionized treatment and outcomes for patients with metastatic melanoma. Specifically, inhibitors aimed at BRAF, NRAS, and C-KIT mutations are now commonly used in tre...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1299710

    authors: Turner MC,Rossfeld K,Salama AK,Tyler D,Beasley G

    更新日期:2017-04-01 00:00:00

  • Adjuvant medical therapy for prostate cancer.

    abstract:IMPORTANCE OF THE FIELD:Prostate cancer is a common cancer and the role of adjuvant medical therapy continues to be investigated. An understanding of the use of adjuvant medical therapy is essential for the appropriate care of prostate cancer patients, especially for those with locally advanced or high-risk disease. A...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.516252

    authors: Sumey C,Flaig TW

    更新日期:2011-01-01 00:00:00

  • Duodenal levodopa infusion for the treatment of Parkinson's disease.

    abstract::Motor fluctuations are a common problem in the long-term management of Parkinson's disease (PD), resulting in disability and impaired quality of life. The relatively short serum half-life (approximately 90 min) of oral levodopa/carbidopa and its erratic absorption due to delayed and inconsistent gastric emptying (a no...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.5.657

    authors: Samanta J,Hauser RA

    更新日期:2007-04-01 00:00:00

  • Pharmacotherapy of hypercholesterolaemia: statins in clinical practice.

    abstract::The objective of this article is to evaluate the roles of the lipid-lowering class of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) in reducing cardiovascular events and to review their mechanism of action based on in vitro and in vivo studies. The clinical outcome of 15 major clinical...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.4.683

    authors: Moghadasian MH,Mancini GB,Frohlich JJ

    更新日期:2000-05-01 00:00:00

  • Pharmacogenetics of colorectal cancer.

    abstract::Colorectal cancer is one of the most common types of cancer in both men and women. Multiple chemotherapy combinations exist; however, there is currently no strategy for individualised therapy selection prior to treatment. Genetic polymorphisms in genes involved in the metabolism, transport or targets for the commonly ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.15.2607

    authors: Marsh S

    更新日期:2005-12-01 00:00:00

  • Nesiritide: a reappraisal of efficacy and safety.

    abstract::The treatment of acute decompensated heart failure (ADHF) remains a therapeutic challenge. Nesiritide was approved by the FDA in 2001 for the treatment of patients with ADHF who have dyspnea at rest or with minimal exertion. Although widely adopted for the treatment of ADHF due to its ability to decrease ventricular f...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.3.361

    authors: Shah SJ,Teerlink JR

    更新日期:2007-02-01 00:00:00

  • Efficacy of indacaterol as a single therapy versus salmeterol/fluticasone therapy in patients with milder chronic obstructive pulmonary disease.

    abstract:INTRODUCTION:In non-exacerbation chronic obstructive pulmonary disease (COPD) with mild lung function impairment, single bronchodilator therapy might be as effective as combined inhaled corticosteroid/bronchodilator therapy, whereas the risk of pneumonia associated with the latter would be practically absent. AREAS CO...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 评论,杂志文章

    doi:10.1517/14656566.2015.1043888

    authors: Ruxandra U,Antoniu SA,Mihaltan F,Boisteanu D

    更新日期:2015-01-01 00:00:00

  • The treatment of neoplastic meningitis.

    abstract::Neoplastic meningitis (NM) is a debilitating complication of cancer that occurs when tumour cells infiltrate the leptomeninges. Treatment often includes direct installation of chemotherapy into the cerebrospinal fluid either by lumbar puncture or the use of a ventricular reservoir, radiation therapy, systemic chemothe...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.5.9.1929

    authors: Armstrong TS,Gilbert MR

    更新日期:2004-09-01 00:00:00

  • Lacosamide in patients with pharmacoresistant epilepsy.

    abstract:INTRODUCTION:Lacosamide is a novel antiepileptic drug licensed in the US and Europe as adjunctive therapy for partial-onset seizures in adults. The efficacy, safety, tolerability and favorable pharmacokinetic profile in the adult population suggest that lacosamide could be of benefit for patients with partial-onset sei...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.713347

    authors: Verrotti A,Loiacono G,Olivieri C,Zulli E,Zaccara G

    更新日期:2012-10-01 00:00:00

  • Second line treatment options for pancreatic cancer.

    abstract:INTRODUCTION:Patients with advanced pancreatic cancer (APC) refractory to first-line therapy have a dismal prognosis and limited therapeutic options, with only one option consisting of nanoliposomal irinotecan in combination with fluorouracil and folinic acid which was approved by FDA based upon results of the phase II...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1369955

    authors: Passero FC Jr,Saif MW

    更新日期:2017-10-01 00:00:00

  • Ceftazidime for respiratory infections.

    abstract:INTRODUCTION:Ceftazidime is a third-generation cephalosporin that has activity against Gram-negative bacilli, including Pseudomonas aeruginosa. The increasing prevalence of antimicrobial resistance and the limited number of antimicrobial agents in development have necessitated a review of the current status of treatmen...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.721777

    authors: Choi SH,Koh Y

    更新日期:2012-10-01 00:00:00

  • Pharmacotherapy for the treatment of vaginal atrophy.

    abstract:INTRODUCTION:Despite its frequency, recognition and therapy of vulvovaginal atrophy (VVA) remain suboptimal. Wet mount microscopy, or vaginal pH as a proxy, allows VVA diagnosis in menopause, but also in young contraception users, after breast cancer, or postpartum. Intravaginal low dose estrogen product is the main th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1574752

    authors: Donders GGG,Ruban K,Bellen G,Grinceviciene S

    更新日期:2019-05-01 00:00:00

  • Pharmacotherapeutic strategies for treating epilepsy in patients with Alzheimer's disease.

    abstract:INTRODUCTION:Alzheimer's disease (AD)-related epileptic comorbidity is now well documented and appears to have been previously underestimated. Prescribing antiepileptic drugs (AEDs) in AD patients aims at preventing seizure-related morbi-mortality and the occurrence of deleterious status epilepticus. At the earlier sta...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1496237

    authors: Cretin B

    更新日期:2018-08-01 00:00:00

  • Ribavirin--current status of a broad spectrum antiviral agent.

    abstract::Ribavirin is a very broad-spectrum virustatic antiviral agent, first synthesised in 1972. It is characterised by low toxicity apart from reversible anaemia, usually mild. Its multiple mechanisms of action mean that viral resistance rarely develops. It can be administered orally, intravenously, or via a nebuliser. It h...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.8.1317

    authors: Snell NJ

    更新日期:2001-08-01 00:00:00